Patient experiences of narcolepsy and idiopathic hypersomnia in the Nordics: a patient journey map
Journal of Sleep Research · 2025
DOI: 10.1111/jsr.14376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Sleep Research, 2025. Verfasst von Märt Vesinurm und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nordic Healthcare Group Oy, Helsinki, Finland. Hauptthemen laut MEDLINE: Narcolepsy, Idiopathic Hypersomnia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharma AB, a subsidiary of Takeda Pharmaceuticals Inc.
Abstract (Originalsprache)
Central disorders of hypersomnolence (CDH) are chronic diseases that significantly impact the lives of affected individuals. We aimed to explore the perspectives of individuals with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), and the challenges they encounter in their daily lives and within the healthcare systems in the Nordics. Interviews with patients ( N = 41) and healthcare professionals ( n = 14) and a patient survey ( n = 70) were conducted in 2022 in Denmark, Sweden, Finland, and Norway to develop a patient journey map that visualises the patient with CDH journey and provides insights into the difficulties faced by these individuals. The patient journey mapping approach was chosen to focus on the processes and experiences of patients, highlighting the challenges they confront. Our findings revealed that the process of receiving a CDH diagnosis, as well as subsequent misdiagnoses and treatment, can be protracted and burdensome. CDH diagnoses remain poorly understood by neurologists, general practitioners, and the public, resulting in adverse consequences, with patients reporting a mean (standard deviation [SD]) time from symptom onset to diagnosis of 8.4 (5.11) years and a mean (SD) of 5.5 (4.17) productive hours lost/day. The available non‐pharmaceutical support for patients with CDH, encompassing medical, psychological, educational, and professional assistance, was insufficient. The generalisability of the findings to one specific diagnosis is limited due to the collective analysis of the CDH. These findings are invaluable for identifying disruptions in the patient with CDH journeys and for designing improved pathways for those with NT1, NT2, and IH in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nordic Healthcare Group Oy, Helsinki, Finland.
- Department of Industrial Engineering and Management, Aalto University School of Science, Espoo, Finland.
- Takeda AS, Vallensbæk Strand, Denmark.
- Takeda AS, Asker, Norway.
- Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden.
- Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
ORCID-Profile: Märt Vesinurm, Anne-Marie Landtblom, Poul Jørgen Jennum
Förderung
- Takeda Pharma AB, a subsidiary of Takeda Pharmaceuticals Inc
Zitieren
APA
Vesinurm, M., Dünweber, C., Rimestad, J., Landtblom, A. M., & Jennum, P. J. (2025). Patient experiences of narcolepsy and idiopathic hypersomnia in the Nordics: a patient journey map. Journal of Sleep Research. https://doi.org/10.1111/jsr.14376
Vancouver
Vesinurm M, Dünweber C, Rimestad J, Landtblom AM, Jennum PJ. Patient experiences of narcolepsy and idiopathic hypersomnia in the Nordics: a patient journey map. Journal of Sleep Research. 2025. doi:10.1111/jsr.14376
BibTeX
@article{Vesinurm2025,
author = {Vesinurm, Märt and Dünweber, Christina and Rimestad, Jesper and Landtblom, Anne-Marie and Jennum, Poul Jørgen},
title = {Patient experiences of narcolepsy and idiopathic hypersomnia in the Nordics: a patient journey map},
journal = {Journal of Sleep Research},
year = {2025},
doi = {10.1111/jsr.14376}
}
EUVIMED